Clinical Trial Update: Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) [Phase 2]

View source ↗

Summary

A Phase 2 trial (LOTUSS) evaluated the safety and tolerability of pirfenidone in systemic sclerosis-related interstitial lung disease (SSc-ILD). The results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Systemic Sclerosis

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Genentech, Inc. | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2015-09-28